Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention

Phosphoinositide 3-Kinases as Potential Targets for Thrombosis Prevention

As integral parts of pathological arterial thrombi, platelets are the targets of pharmacological regimens designed to treat and prevent thrombosis. A detailed understanding of platelet biology and function is thus key to design treatments that prevent thrombotic cardiovascular disease without signif...

Full description

Bibliographic Details
Main Authors:	Natasha M. Setiabakti, Pia Larsson, Justin R. Hamilton
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	International Journal of Molecular Sciences
Subjects:	platelets thrombosis phosphoinositide 3-kinase PI3K antiplatelet therapy
Online Access:	https://www.mdpi.com/1422-0067/23/9/4840

Similar Items

PI3K inhibitors in thrombosis and cardiovascular disease
by: Tom N. Durrant, et al.
Published: (2020-01-01)

Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
by: Ebru Aydin, et al.
Published: (2021-01-01)

Phosphatidylinositol 3‐monophosphate: A novel actor in thrombopoiesis and thrombosis
by: Colin Valet, et al.
Published: (2020-05-01)

Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination
by: Laura Di Blasio, et al.
Published: (2017-03-01)

Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth
by: Ouma Cisse, et al.
Published: (2019-11-01)

Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review
by: Duy C. Tran, MD, et al.
Published: (2022-06-01)

Regulation of Phosphoinositide Signaling by Scaffolds at Cytoplasmic Membranes
by: Tianmu Wen, et al.
Published: (2023-08-01)

Loss of Class III Phosphoinositide 3-Kinase Vps34 Results in Cone Degeneration
by: Ammaji Rajala, et al.
Published: (2020-11-01)

“Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia”
by: Stefano Ratti, et al.
Published: (2021-05-01)

Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion
by: Michele N. Pham, et al.
Published: (2018-12-01)

Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors
by: Viviana Mannella, et al.
Published: (2021-03-01)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
by: Niamh M. Keegan, et al.
Published: (2021-03-01)

The Inhibition of Phosphoinositide-3 Kinases Induce Resolution of Inflammation in a Gout Model
by: Izabela Galvão, et al.
Published: (2019-01-01)

Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta
by: Marjolein W. J. Wentink, et al.
Published: (2018-03-01)

Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling
by: Tania Maffucci, et al.
Published: (2020-09-01)

Immunodeficiency due to a novel variant in PIK3CD: a case report
by: Niloofar Shashaani, et al.
Published: (2023-07-01)

Propolis Suppresses UV-Induced Photoaging in Human Skin through Directly Targeting Phosphoinositide 3-Kinase
by: Da Hyun Kim, et al.
Published: (2020-12-01)

Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases
by: Gillian L. Dornan, et al.
Published: (2018-03-01)

Targeting Phosphoinositide 3-Kinase – Five Decades of Chemical Space Exploration
by: Chiara Borsari, et al.
Published: (2021-12-01)

Activated Phosphoinositide 3-Kinase Delta Syndrome 1: Clinical and Immunological Data from an Italian Cohort of Patients
by: Giulio Tessarin, et al.
Published: (2020-10-01)

Phosphoinositide 3-kinase: friend and foe in cardiovascular disease
by: Alessandra eGhigo, et al.
Published: (2015-08-01)

The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
by: Claudia Kalla, et al.
Published: (2024-05-01)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
by: Daniel A. Rodrigues, et al.
Published: (2019-05-01)

Phosphoinositide Signaling in Immune Cell Migration
by: Ruchi Kakar, et al.
Published: (2023-11-01)

Inhibition of Vps34 and p110δ PI3K Impairs Migration, Invasion and Three-Dimensional Spheroid Growth in Breast Cancer Cells
by: Marzia Di Donato, et al.
Published: (2022-08-01)

Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
by: Nikos Koundouros, et al.
Published: (2018-05-01)

The PI-3-Kinase P110α Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis
by: María Montes-Casado, et al.
Published: (2021-06-01)

Targeting PDK1 for Chemosensitization of Cancer Cells
by: Aikaterini Emmanouilidi, et al.
Published: (2017-10-01)

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
by: Khine S. Shan, et al.
Published: (2024-02-01)

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
by: Maria Elena Maccari, et al.
Published: (2018-03-01)

Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome
by: Alison M. Condliffe, et al.
Published: (2018-03-01)

Targeting phosphoinositide signaling in cancer: relevant techniques to study lipids and novel avenues for therapeutic intervention
by: Alicia Llorente, et al.
Published: (2023-10-01)

Anti-inflammatory effects of curcumin are associated with down regulating microRNA-155 in LPS-treated macrophages and mice
by: Feiya Ma, et al.
Published: (2017-01-01)

The role of phosphoinositide 3-kinase subunits in chronic thyroiditis
by: Wojciechowska-Durczynska Katarzyna, et al.
Published: (2012-12-01)

New Insights into the Role of Phosphoinositide 3-Kinase Activity in the Physiology of Immature Oocytes: Lessons from Recent Mouse Model Studies
by: So-Youn Kim, et al.
Published: (2018-06-01)

Dihydrotestosterone induces SREBP-1 expression and lipogenesis through the phosphoinositide 3-kinase/Akt pathway in HaCaT cells
by: Zhou Bing-rong, et al.
Published: (2012-11-01)

Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy
by: David Michalovich, et al.
Published: (2018-02-01)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
by: Xueqin Huang, et al.
Published: (2023-12-01)

A phase II study of buparlisib in relapsed or refractory thymomas
by: Mohammad I. Abu Zaid, et al.
Published: (2022-10-01)

Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome
by: Zexi Yin, et al.
Published: (2021-12-01)